Abstract
Fifty-eight Nigerian outpatients with documented erectile dysfunction (ED) received open-label sildenafil citrate (Viagra®) for 8 weeks. The 50-mg starting dose could be adjusted to 100 or 25 mg based on response and tolerability. The International Index of Erectile Function (IIEF) Questionnaire, a global efficacy question, and intercourse data recorded in a patient event log were used to assess efficacy. Frequency of penetration and maintained erection were both significantly enhanced (P<0.0001); 95% of patients reported improved erections and 81% of all attempts at intercourse were successful. Orgasmic function, sexual desire, intercourse satisfaction, and overall satisfaction also improved significantly (P<0.0001). The most frequent adverse events (all-cause) were headache (17%) and myalgia (3%); only one patient discontinued treatment because of headache, which was considered unrelated to sildenafil. Oral sildenafil significantly improved erectile function and was well tolerated in this trial of Nigerian men suffering from ED. Our results are consistent with reports from other countries.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 8 print issues and online access
$259.00 per year
only $32.38 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Boolell M, Gepi-Attee S, Gingell JC, Allen MJ . Sildenafil, a novel effective oral therapy for male erectile dysfunction. Br J Urol 1996; 78: 257–261.
Burnett AL . Nitric oxide in the penis: physiology and pathology. J Urol 1997; 157: 320–324.
Wagner G, Saenz de Tejada I . Update on male erectile dysfunction. BMJ 1998; 316: 678–682.
Boolell M et al. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 1996; 8: 47–52.
Goldstein I et al. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998; 338: 1397–1404.
Rosen RC et al. The International Index of Erectile Function (IIEF): a multidimensional scale for the assessment of erectile dysfunction. Urology 1997; 49: 822–830.
Morales A et al. Clinical safety of oral sildenafil citrate (Viagra™) in the treatment of erectile dysfunction. Int J Impot Res 1998; 10: 69–73.
Acknowledgements
This study was supported by a research grant from Pfizer Inc.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Osegbe, D., Shittu, O., Aghaji, A. et al. Sildenafil citrate (Viagra®) for the treatment of erectile dysfunction in Nigerian men. Int J Impot Res 15 (Suppl 1), S15–S18 (2003). https://doi.org/10.1038/sj.ijir.3900972
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.ijir.3900972
Keywords
This article is cited by
-
Sildenafil citrate (Viagra) treatment for erectile dysfunction: an updated profile of response and effectiveness
International Journal of Impotence Research (2006)
-
Erectile dysfunction in the Africa/Middle East Region: epidemiology and experience with sildenafil citrate (Viagra®)
International Journal of Impotence Research (2003)